← All organizations
Highest phase reached
Phase 4
First clinical trial
Dec 1, 2005Last known activity
Nov 4, 2025
Timeline
2000s
- Jun 1, 2005
National Cancer Institute, France— Founded
Drugs by trial phase (107 distinct, 73 trials)
Phase 4 (3 own, 0 via acquisition)
Phase 3 (48 own, 0 via acquisition)
Phase 2 (47 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Other trials (5 own, 0 via acquisition)
Indications
Studied for
- Ascites
- Breast Neoplasms
- Carcinoma
- Carcinoma, Islet Cell
- Carcinoma, Neuroendocrine
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Carcinoma, Squamous Cell
- Carotid Body Tumor
- Central Nervous System Neoplasms
- Colorectal Neoplasms
- Disease Progression
- Endometrial Neoplasms
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Glioblastoma
- Glioma
- Head and Neck Neoplasms
- Hematologic Neoplasms
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Melanoma
- Microsatellite Instability
- Myelodysplastic Syndromes
- Neoplasm Metastasis
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Second Primary
- Neoplastic Cells, Circulating
- Nervous System Neoplasms
- Neuroblastoma
- Osteosarcoma
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Paraganglioma
- Penile Neoplasms
- Pheochromocytoma
- Polycythemia
- Polycythemia Vera
- Preleukemia
- Prostatic Neoplasms
- Recurrence
- Sarcoma
- Skin Neoplasms
- Squamous Cell Carcinoma of Head and Neck
- Thromboembolism
- Thyroid Diseases
- Thyroid Neoplasms
- Triple Negative Breast Neoplasms
- Uterine Cervical Neoplasms
- Venous Thromboembolism
Recent trials (50)
- NCT07243470CollaboratorPhase 1/Phase 2Nov 4, 2025
- NCT07192068CollaboratorPhase 2Oct 30, 2025
- NCT06653777CollaboratorPhase 2Dec 15, 2024
- NCT06333314CollaboratorPhase 2Jul 23, 2024
- NCT05615818CollaboratorPhase 3Jul 18, 2024
- NCT06364631CollaboratorPhase 3Apr 12, 2024
- NCT05986071CollaboratorPhase 1/Phase 2Apr 1, 2024
- NCT05821231CollaboratorPhase 1Dec 12, 2023
- NCT05888857CollaboratorPhase 2Sep 30, 2023
- NCT05180695CollaboratorPhase 1/Phase 2Apr 15, 2022
- NCT05210413CollaboratorPhase 1/Phase 2Apr 1, 2022
- NCT04945148CollaboratorPhase 2Dec 31, 2021
- NCT04747054CollaboratorPhase 3Nov 15, 2021
- NCT05255653CollaboratorPhase 2/Phase 3Nov 11, 2021
- NCT04899492CollaboratorN/ASep 29, 2021
Details
- Founded
- Paris, FR Jun 1, 2005
- Last known activity
- Nov 4, 2025